DIRS.INFO The most relevant business & tech news

☆ Stocks making the biggest moves premarket: Meta, Teladoc, Harley-Davidson, Southwest Airlines and more
▼ + stars: | 2023-04-27 | by ( Sarah Min | ) www.cnbc.com time to read: +6 min

Teladoc Health – The telemedicine company saw its stock soar more than 7% after revenue topped analyst estimates in the latest quarter. The company also raised the low end of its revenue and adjusted EBITDA guidance, although it posted a wider-than-anticipated loss in the latest quarter. Harley-Davidson – Harley-Davidson jumped 4.4% after the motorcycle maker topped earnings and revenue expectations, according to consensus estimates from Refinitiv. Honeywell International – Honeywell advanced 1.8% after surpassing earnings and revenue expectations in its latest quarter. ServiceNow – Shares declined 1.1% premarket after a 17% runup year-to-date entering its latest earnings.

☆ CEOs of Pioneer Natural Resources and Bristol-Myers Squibb to retire
▼ + stars: | 2023-04-27 | by ( ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailCEOs of Pioneer Natural Resources and Bristol-Myers Squibb to retireCNBC's 'Squawk Box' crew reports on two executives planning to step down from their respective companies at the end of the year.

☆ Bristol Myers posts lower Q1 sales as Revlimid falls
▼ + stars: | 2023-04-27 | by ( Michael Erman | ) www.reuters.com time to read: +2 min

April 27 (Reuters) - Drugmaker Bristol Myers Squibb (BMY.N) on Thursday said its first-quarter sales fell from last year, hurt by generic competition for its cancer drug Revlimid. The drugmaker also announced on Wednesday evening that its Chief Executive Officer Giovanni Caforio plans to step down from the role in November, to be replaced by the company's current Chief Commercialization Officer Chris Boerner. Analysts, on average, expected sales of $11.49 billion in the quarter, according to Refinitiv data. Bristol Myers said it earned around $2.05 a share in the quarter, excluding one-time items. Sales of Revlimid, which began facing generic competition last year, fell to $1.75 billion in the quarter, down 37% from $2.8 billion last year.

☆ Morning Bid: Fresh spur from Meta and Europe's banks
▼ + stars: | 2023-04-27 | by ( ) www.reuters.com time to read: +5 min

Perhaps even more surprising, Europe's big banks are wowing the gallery too - showing limited, if any, fallout from the failure of ailing Credit Suisse at the end of the quarter. And so the glass appears half full again despite background tensions around regional U.S. banks and as wider markets brace for several weeks of a U.S. debt ceiling standoff. With Amazon reporting later, its stock rose another 2% ahead of the bell too. The U.S. House of Representatives on Wednesday narrowly passed a bill to raise the government's $31.4 trillion debt ceiling that includes sweeping spending cuts over the next decade. The dollar was marginally weaker, with crude oil prices struggling to recover from their latest lunge lower this week.

☆ Bristol Myers CEO Caforio steps down
▼ + stars: | 2023-04-26 | by ( ) www.reuters.com time to read: +1 min

[1/2] A sign stands outside a Bristol Myers Squibb facility in Cambridge, Massachusetts, U.S., May 20, 2021. REUTERS/Brian Snyder/File PhotoCompanies Bristol-Myers Squibb Co FollowApril 26 (Reuters) - Bristol Myers Squibb Co (BMY.N) said on Wednesday CEO Giovanni Caforio, who has been in the role since 2015, has decided to step down from his position. Outgoing CEO Giovanni will continue as executive chairman of the company's board. Bristol Myers is due to report first-quarter financial results on Thursday. Bristol Myers shares rose 0.39% to $68.29 in after-hours trading.

☆ Bristol-Myers CEO Giovanni Caforio to Step Down
▼ + stars: | 2023-04-26 | by ( Jared S. Hopkins | Laura Cooper | ) www.wsj.com time to read: 1 min

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com. https://www.wsj.com/articles/bristol-myers-ceo-giovanni-caforio-to-leave-drugmaker-5de94f38

☆ Climate-Disclosure Rules Are Coming. Here’s How Companies Are Adapting.
▼ + stars: | 2023-04-25 | by ( Dieter Holger | ) www.wsj.com time to read: +5 min

International jurisdictions and the U.S. Securities and Exchange Commission are expected to finalize rules by this summer that will require public companies to report their greenhouse-gas emissions. Direct suppliers are known as tier 1 with that number increasing the deeper you go down the supply chain. Partnerships with suppliers: Large companies are working with small suppliers to overcome hurdles to accessing renewable power supplies, a relatively straightforward way to cut emissions. In October, it said its first group was five companies, including Amy’s Kitchen Inc., Levi Strauss & Co. and J.M. Targets for lower-emission alternatives: Nestlé SA is paying a premium to farmers in its supply chain that cut emissions by following regenerative farming practices.

☆ These are the places most at risk from record-breaking heat waves as the planet warms
▼ + stars: | 2023-04-25 | by ( Laura Paddison | ) edition.cnn.com time to read: +5 min

They identified Afghanistan, Papua New Guinea and Central America – including Guatemala, Honduras and Nicaragua – as “hot spots” for high-risk heat waves. Not only is there high potential for record-breaking extreme heat, but the impacts will be intensified by the huge difficulties the country already faces, he said. “When a really extreme heat wave does finally come along, then there are instantly going to be a lot of problems,” Mitchell said. Heat waves have a wide-ranging negative impact. They also take a heavy toll on human health, and extreme heat is one of the deadliest natural disasters.

☆ NASA detects first seismic waves within Mars' core
▼ + stars: | 2023-04-24 | by ( Ashley Strickland | ) edition.cnn.com time to read: +5 min

During these events, InSight detected for the first time seismic waves traveling through the Martian core. “More than a hundred years later, we’re applying our knowledge of seismic waves to Mars. With InSight, we’re finally discovering what’s at the center of Mars and what makes Mars so similar yet distinct from Earth.”The NASA InSight Mars lander studied the interior of Mars for four years. Planetary core offers clues on evolutionEarth has a liquid outer core and a solid inner core, but the Martian core appears to be made entirely from liquid. “We’ve made the very first observations of seismic waves travelling through the core of Mars.

☆ Big Tech earnings, crucial inflation call — here comes the biggest week of earnings season
▼ + stars: | 2023-04-22 | by ( Zev Fima | ) www.cnbc.com time to read: +9 min

Stocks stuck to a holding pattern this week as investors brace for an incoming wave of Big Tech earnings and the Fed's favorite inflation reading. Earnings reports have generally been better than expected so far this first quarter. Humana (HUM) reports before the bell Wednesday; Meta Platforms and Pioneer Natural Resources (PXD) report after the bell Wednesday. ET: Personal Spending & Income (includes PCE Price Index) Club trades this week Just one trade: We added 150 shares of Coterra Energy (CTRA) on Wednesday. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

☆ What to watch for in the markets in the week ahead: Monster tech earnings, then sell in May?
▼ + stars: | 2023-04-21 | by ( Scott Schnipper | ) www.cnbc.com time to read: +6 min

More than one third (35%) of the S & P 500 reports earnings next week — including megacaps Microsoft, Alphabet, Meta Platforms and Amazon — versus less than 12% in the week just ended and only 2% last week. So far this quarter, S & P 500 earnings are running 4.7% below the same period a year ago, Refinitiv data shows. Back then, the S & P 500 fell 19.4% from its April high to a low on October 3. Meanwhile, next week is the last full trading week before Wall Street's old adage to "sell in May and go away" takes hold. ET: FHFA Home Price index (February); S & P Case-Shiller home price indexes (February) 10:00 a.m.

LONDON, April 20 (Reuters Breakingviews) - Film and TV adaptations of video games have a chequered history. But Nintendo’s “Super Mario”, along with HBO’s “The Last of Us”, is flipping the script. Jefferies analysts estimate that the “Super Mario” movie could add $350 million to Nintendo’s operating profit – equivalent to around 8% of its total for the year ending March 2022. The success of recent adaptations may lead media giants like Walt Disney (DIS.N), Comcast and Netflix to wonder what other goodies lie in video game companies. Follow @olivertaslic on TwitterCONTEXT NEWS“The Super Mario Bros. Movie”, an animated film co-financed by Nintendo and Universal Pictures, was released in North America on April 5.

☆ They Saw the Horrific Aftermath of a Mass Shooting. Should We?
▼ + stars: | 2023-04-20 | by ( Jay Kirk | ) www.nytimes.com time to read: +12 min

Jeff decided that he and Sam would be the only two permitted to have phones inside, in order to limit photographs. It was something Jeff learned to do from the nurses at Bristol Hospital a million years ago when he was a paramedic. He had already made the mistake when one fluttered out as he was dumping an uneaten lunch into the trash. They would set up staging tables in the tent for mass processing of the evidence, nothing they’d ever done at this scale. The problem was that during these interruptions it was not as if they could just step outside for a break.

☆ Grocery app Getir, once worth $11.8 billion, sees valuation almost halved with new funding, sources say
▼ + stars: | 2023-04-19 | by ( Callum Burroughs | ) www.businessinsider.com time to read: +3 min

Getir, one of the biggest remaining grocery apps, has raised $500 million, per sources. But its valuation has been almost halved to around $6.5 billion, from $11.8 billion. Other existing shareholders added another $150 million to $200 million to the round, two further sources said. The deal is a 45% markdown on the $11.8 billion price tag that was placed on Getir during its last fundraise in March 2022. Getir could have been valued even lower but the deal came with a high liquidation preference, the sources added.

☆ King Charles backs research into monarchy's slave links
▼ + stars: | 2023-04-06 | by ( Michael Holden | ) www.reuters.com time to read: +2 min

[1/3] Britain's King Charles III arrives on a boat for a trip at the port in Hamburg, Germany, Friday, March 31, 2023. Matthias Schrader/Pool via REUTERSLONDON, April 6 (Reuters) - King Charles has given his support to research that will examine the British monarchy's links to slavery, Buckingham Palace said on Thursday, after a newspaper report said a document showed a historical connection with a transatlantic slave trader. The issue of the British Empire's slavery links and calls for possible reparations from the monarchy has been growing in the Caribbean where Charles remains head of state of a number of countries including Jamaica and the Bahamas. That process had continued with "vigour and determination" since Charles succeeded his mother on the throne last September, it said. "Given the complexities of the issues it is important to explore them as thoroughly as possible," the Palace statement said.

☆ Play defense with these fortress stocks in the second quarter
▼ + stars: | 2023-04-02 | by ( Michelle Fox | ) www.cnbc.com time to read: +9 min

Bahnsen's investment philosophy focuses specifically on high-quality stocks that have a high dividend yield, along with consistent increases. One of his favorite plays is Procter & Gamble , which currently has a dividend yield of 2.5%. EOG has a 2.9% dividend yield and also has been paying a special dividend. Health-care names Names in the health-care sector are generally considered defensive. Quanta Services has a dividend yield on the lower end, at 0.2%.

If successful, Amgen would claim ownership of all antibodies that inhibit the PCSK9 protein, the mechanism of action for both Repatha and Praluent. Other companies could then do the same with their own antibody treatments in other disease areas. The case might also affect newer technologies used in medicine, such as CRISPR gene editing and messenger RNA, she said. A Washington, D.C.-based federal appeals court that covers U.S. patent cases invalidated Amgen's patent claiming ownership of all PCSK9 inhibitors as a whole in 2021. Amgen sued Sanofi and Regeneron in 2014.

☆ It's time to buy drug stocks, says Cramer
▼ + stars: | 2023-03-15 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailIt's time to buy drug stocks, says CramerMad Money host Jim Cramer explains why he believes now is the time to buy drug stocks, like Bristol-Myers.

☆ Here’s how we navigated three sessions of SVB-sparked chaos and Tuesday’s bounce
▼ + stars: | 2023-03-14 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

The S & P 500 climbed roughly 1% in afternoon Tuesday trading, clawing back only some of its 3.4% decline between Thursday and Monday's close. We spent Monday morning looking for things to buy in what our trusted S & P Oscillator signaled was an oversold market. In the three sessions Thursday through Monday, both stocks underperformed the S & P 500 as they fell 5.4% and 4.4%, respectively. Palo Alto didn't get either nod, but we think it's only a matter of time before its added to the index. While S & P 500 constituency wasn't in the cards this time, we will continue to add to our position into weakness.

[1/3] A pharmacist holds a bottle of the drug Eliquis, made by Bristol Myers Squibb and Pfizer, at a pharmacy in Provo, Utah, U.S. January 9, 2020. The government will launch the negotiation process in September by naming the first drugs it plans to target. "We couldn't have the other parts of the IRA without this Medicare negotiation," said Sean Dickson, director of the West Health Policy Center, a non-partisan healthcare think tank. Eliquis, which Bristol Myers (BMY.N) shares with Pfizer (PFE.N), Ibrance, and Imbruvica, sold by AbbVie and Johnson & Johnson (JNJ.N), appear on every list. Pfizer, Novo Nordisk and J&J declined to comment on the likelihood their drugs would be included in the first round of negotiations.

☆ Dwarf elephants? Giant rats? Strange island creatures at high risk
▼ + stars: | 2023-03-09 | by ( Will Dunham | ) www.reuters.com time to read: +4 min

WASHINGTON, March 9 (Reuters) - A dwarf elephant the size of a Shetland pony once roamed the Mediterranean island of Cyprus. They were examples of the "island effect," a rule in evolutionary biology describing how large-bodied species tend to downsize on islands while small-bodied species upsize. Extinction risk was seen highest among species that underwent more extreme body size shifts compared to mainland relatives. But small-bodied species, because there is a decreased risk from predators on islands, are emancipated from evolutionary constraints on their size. It once was home to a dwarf elephant relative, giant rats and a giant stork, as well as a dwarf human species - Homo floresiensis, nicknamed the "Hobbit," standing just 3-1/2 feet tall (106 cm) tall.

☆ Bank of America sees lithium surplus in 2023 as demand eases
▼ + stars: | 2023-03-07 | by ( Lee Ying Shan | ) www.cnbc.com time to read: +1 min

"We see a lot of supply coming out from lithium mines ... We are expecting 38% lithium supply growth this year. That's why 2023 is likely to turn into a surplus year for lithium," Zhao told CNBC. She also said she expects China's electric vehicle demand growth to slow from 95% last year to 22% this year. In the two years ending December 2021, lithium carbonate spot prices rose 5% to stand at 277,500 yuan per ton. But subsequently surged to a record high of almost 600,000 yuan per ton in November 2022, more than 12 times January 2021 prices.

Circuit Court of Appeals that said because her overtime pay lawsuit was filed in Pennsylvania, only workers from that state could join. The Supreme Court last year declined to take up appeals of those cases. Under the FLSA, workers can file "collective actions" that are similar to class action lawsuits but have some key procedural differences, including that other workers must opt in to be included. The 3rd Circuit upheld that ruling last year, prompting Fischer's Supreme Court petition. The case is Fischer v. Federal Express Corp, U.S. Supreme Court, No.

☆ Top 10 things the Club is watching in the stock market Monday
▼ + stars: | 2023-03-06 | by ( Jeff Marks | ) www.cnbc.com time to read: +4 min

Morgan Stanley's Adam Jonas raises his price target on Ferrari (RACE) to $310 per share from $280. Pfizer (PFE) started with a neutral (hold) rating. Jefferies downgrades RH (RH), formerly known as Restoration Hardware, to hold, price target to $298 per share on concerns the luxury market is struggling to stabilize. Calls the chipmaker top cloud pick with a $275-per-share price target, ahead of multiple catalysts. General Electric (GE) coverage transferred at JPMorgan, which maintains neutral (hold) rating but increases price target to $88 per share.

☆ SoftBank's Arm rebuffs London by choosing U.S. listing
▼ + stars: | 2023-03-03 | by ( Paul Sandle | ) www.reuters.com time to read: +3 min

The company did not completely rule out an eventual London listing, saying it intended to consider a subsequent IPO there in due course, without providing further details. London worked hard to get the listing, with Prime Minister Rishi Sunak and Arm Chief Executive Rene Haas meeting in Downing Street last month, according to reports. The loss follows a decision by Dublin-based building materials giant CRH on Thursday to move its primary listing from London to the United States. Arm has pushed into markets beyond smartphones, such as data center servers, where its low-power designs can cut energy use. It immediately identified New York as its preferred destination, where the company will join the likes of Intel, Qualcomm and Nvidia.

Search resuls for: "BRISTOL"

25 mentions found